Retrocyclin-101
Retrocyclin-101 (RC-101) is a synthetic cyclic θ-defensin, a broad-spectrum antimicrobial peptide with anti-pathogen (covering viruses, bacteria and fungi) activity and anti-inflammatory activity. Retrocyclin-101 exhibits significant inhibitory activity against HIV, SARS-CoV-2, flaviviruses, influenza viruses, HSV-1/2, Staphylococcus aureus and others. Retrocyclin-101 inhibits TLR4 and TLR2-mediated signal transduction and reduces pro-inflammatory cytokine expression.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 536757-16-1
- Formel: C74H130N28O19S6
- Molecular Weight:1908.39
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
In Vitro
Retrocyclin-101 (50 μM; 1 h) inhibits the infection of H1299 cells by SARS-CoV-2 spike protein-pseudotyped lentivirus, but this effect is only observed when it is pre-incubated with viral particles (no such effect occurs when pre-incubated with cells), and serum abrogates this effect[1].
Retrocyclin-101 (0.5-5 μM; 1 h) inhibits the binding of recombinant prefusion-stabilized SARS-CoV-2 spike protein to ACE2 in a concentration-dependent manner, and reduces the binding rate to approximately 25% of that in the control group at 5 μM after pre-incubation at 37°C[1].
Retrocyclin-101 (3-50 μM; 1-24 h) inhibits natural SARS-CoV-2 infection in Vero E6 cells; its IC50 is 29 μM without pre-incubation with the virus; when pre-incubated with the virus for 1 h under serum-free conditions, it exerts strong inhibitory activity at a concentration of 50 μM[1].
Retrocyclin-101 (0-50 μM; 47 h) potently inhibits ZIKV PRVABC59 infection in Vero cells, with an IC50 of 7.033 μM[2].
Retrocyclin-101 (0-50 μM; 71 h) inhibits ZIKV MR766 infection in Vero cells, with an IC50 of 15.58 μM[2].
Retrocyclin-101 (0-100 μM) significantly reduces the viral titers of ZIKV PRVABC59 and MR766 in Vero cells and U251 glioma cells in a dose-dependent manner[2].
Retrocyclin-101 (40 μM; 48-72 h) inhibits infections by ZIKV PRVABC59 and MR766 in Vero cells during the viral entry and replication stages, but does not act through direct virucidal activity or blocking cellular receptors[2].
Retrocyclin-101 (25-50 μM; 50 h) inhibits ZIKV replication in BHK-21 cells but has no effect on the translation of initial replicon RNA[2].
Retrocyclin-101 (0-50 μM; 24 h) inhibits the activity of JEV NS2B-NS3 serine protease in BHK-21 cells, reduces the expression level of NS3 and increases the content of unprocessed polyprotein precursors at lower concentrations[2].
Retrocyclin-101 (0-50 μM; 24 h) inhibits JEV AT31 infection in BHK-21 and U251 cells, with an IC50 of 10.67 μM[2].
Retrocyclin-101 (50 μM; 24 h) inhibits wild-type (WT), N154A, H144A, and Q258A strains of JEV in BHK-21 cells, whereas the DE mutant and T410A JEV strains are resistant to RC-101[2].
Retrocyclin-101 can be cleaved from its GFP fusion partner in vitro by Factor Xa protease; partial cleavage occurs naturally in chloroplast extracts of plastid-transformed tobacco due to endogenous Factor Xa-like activity[3].
Retrocyclin-101 (2.5-20 μM; 16 h) potently inhibits the growth of Staphylococcus aureus nasal colonizing strains D20-7, D535-6, D30 and clinical strain USA300 in a concentration-dependent manner; specifically, at a concentration of 20 μM, the growth inhibition duration of nasal colonizing strains exceeds 10 h, and that of USA300 reaches 5 h[4].
Retrocyclin-101 (2.5-10 μM; 0.25-9 h) is a rapidly acting, concentration-dependent bactericide active against Staphylococcus aureus nasal carriage strains D20-7, D535-6, D30 and clinical strain USA300; it achieves complete growth inhibition within 30 min at 10 μM and retains activity even against high bacterial inocula[4].
Retrocyclin-101 (1-10 μg/tissue; 9 h) inhibits the adhesion and survival of Staphylococcus aureus nasal colonization strains D20-7, D535-6, D30 and clinical strain USA300 on human nasal epithelial cells (RPMI 2650), with 10 μg/tissue completely blocking bacterial adhesion[4].
Retrocyclin-101 (4-20 μg/tissue; 9 h) completely inhibits the adhesion of S. aureus nasal colonization strain D20-7 to organotypic human airway epithelium at a concentration of 20 μg/tissue[4].
Retrocyclin-101 (30 μg/mL; 30-60 min) inhibits TRIF- and MyD88-dependent TLR4-mediated proinflammatory cytokine gene expression in human monocyte-derived macrophages[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human monocyte-derived macrophages
-
Concentration:30 μg/mL with 100 ng/mL LPS
-
Incubation Time:30, 60 min
-
Result:Inhibited LPS-induced IL-6, IFN-β, TNF-α, and IL-1β mRNA expression at 30 and 60 min post-stimulation.
Caused significant reduction of all measured cytokines compared to mock-treated cells.
-
Cell Line:HEK293T cells transfected with TLR4-FLAG and TLR4-CFP
-
Concentration:30 μg/mL
-
Incubation Time:30 min
-
Result:Did not inhibit the co-immunoprecipitation of TLR4-CFP with TLR4-FLAG, indicating no disruption of ligand-independent TLR4 oligomerization.
In Vivo
Retrocyclin-101 (100 μg/mouse; i.v.; daily; days 2-6 post-infection) confers significant protection against influenza A virus (PR8) infection in mice, increasing survival and reducing clinical severity when administered therapeutically starting 2 days post-infection[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (female, 6-8-week-old, WT)[5]
-
Dosage:100 μg/mouse
-
Administration:i.v.; daily; days 2-6 post-infection
-
Result:Increased mouse survival post-PR8 infection.
Reduced PR8-induced clinical symptoms, with lower mean clinical scores (ranging 0-5, with 5 = moribund) compared to controls over the 14-day monitoring period.
Chemical Information
-
CAS. Nr. 536757-16-1
-
Molecular Weight 1908.39
-
Formel C74H130N28O19S6
-
Synonyms
RC-101
-
Sequence
Gly-Ile-Cys-Arg-Cys-Ile-Cys-Gly-Lys-Gly-Ile-Cys-Arg-Cys-Ile-Cys-Gly-Arg (Disulfide bridge:Cys3-Cys16;Cys5-Cys14;Cys7-Cys12)
-
Sequence Shortening
GICRCICGKGICRCICGR (Disulfide bridge:Cys3-Cys16;Cys5-Cys14;Cys7-Cys12)
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cotton Pellet Granuloma
Cotton pellet granuloma is a classical in vivo chronic inflammation model used to evaluate the anti-inflammatory potential of test substances by measuring their ability to inhibit granuloma tissue formation around an implanted foreign body (cotton pellet) in rodents. The method is based on the biological response to a sterile implanted material, which induces proliferative phase inflammation characterized by fibroblast proliferation and collagen-rich granuloma formation, and the final readout reflects the extent of chronic inflammatory tissue growth surrounding the pellet. In multiple preclinical pharmacological evaluations, inhibition of cotton pellet-induced granuloma formation has been used as an indicator of anti-inflammatory activity in both synthetic and natural product screening contexts.
-
Carrageenan-Induced Paw Edema
Carrageenan-induced paw edema is an acute inflammation model in which intraplantar injection of carrageenan induces localized inflammatory swelling characterized by vascular permeability, leukocyte infiltration, and production of inflammatory mediators such as prostaglandins and cytokines, making it widely used to evaluate anti-inflammatory agents in vivo. The resulting paw volume or thickness increase is quantified over time as a direct readout of inflammatory intensity and drug efficacy, typically reflecting cyclooxygenase-mediated prostaglandin-driven edema formation and immune cell recruitment in peripheral tissue[20].
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Reinheit & Dokumentation
Verweise
[1]. Kudryashova E, et al. Inhibition of SARS-CoV-2 Infection by Human Defensin HNP1 and Retrocyclin RC-101. J Mol Biol. 2022;434(6):167225. [Content Brief]
[2]. Jia X, et al. Mechanism through Which Retrocyclin Targets Flavivirus Multiplication. J Virol. 2021;95(15):e0056021. [Content Brief]
[3]. Lee SB, et al. Expression and characterization of antimicrobial peptides Retrocyclin-101 and Protegrin-1 in chloroplasts to control viral and bacterial infections. Plant Biotechnol J. 2011;9(1):100-115. [Content Brief]
[4]. Lamers RP, et al. Characterization of the retrocyclin analogue RC-101 as a preventative of Staphylococcus aureus nasal colonization. Antimicrob Agents Chemother. 2011;55(11):5338-5346. [Content Brief]
[5].
Prantner D, et al. The θ-defensin retrocyclin 101 inhibits TLR4- and TLR2-dependent signaling and protects mice against influenza infection. J Leukoc Biol. 2017 Oct;102(4):1103-1113.
[Content Brief]
[6]. Lee SB, et al. Expression and characterization of antimicrobial peptides Retrocyclin-101 and Protegrin-1 in chloroplasts to control viral and bacterial infections. Plant Biotechnol J. 2011 Jan;9(1):100-15. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Keywords
- Retrocyclin-101
- 536757-16-1
- RC-101
- Retrocyclin101
- Retrocyclin 101
- RC101
- RC 101
- Bacterial
- HSV
- Fungal
- Influenza Virus
- Toll-like Receptor (TLR)
- Flavivirus
- Ser/Thr Protease
- SARS-CoV
- HIV
- SARS-CoV-2 Spike protein
- Japanese encephalitis virus E protein DIII DE loop
- Erwinia carotovora
- TLR4
- Staphylococcus aureus
- Zika virus NS2B-NS3 serine protease
- TLR2
- HIV-1
- tobacco mosaic virus
- ACE2
- Inhibitor
- inhibitor
- inhibit